Global Non-Cystic Fibrosis Bronchiectasis Market Forecast 2029: Size, Share, and Competitive Landscape
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Projected Valuation Of The Non-Cystic Fibrosis Bronchiectasis Market In The Coming Years?
The market size for non-cystic fibrosis bronchiectasis has seen a robust growth in recent years. The market is projected to increase from $3.5 billion in 2024 to $3.7 billion in 2025, at a compound annual growth rate (CAGR) of 5.8%. Factors contributing to the growth during the historic period include an increase in incidence and prevalence, developed diagnostic technologies, an expanding elderly population, government support and funding, enhancement in healthcare infrastructure, amplified diagnosis awareness, a rising geriatric population, and environmental exposure.
Anticipated robust expansion is on the horizon for the non-cystic fibrosis bronchiectasis market, with projections predicting growth to $4.68 billion by 2029, presenting a compound annual growth rate (CAGR) of 6.1%. This expected upswing during the forecasting window may be credited to progressive strides in individualized medicine, the rise of new biomarkers, bolstered investments towards respiratory medicine, burgeoning research and development activities, public health movements, the worldwide aging demographic, and the evolution of specialized treatment options. Noteworthy forward-looking trends encompass digital health services, an emphasis on specialized treatments, the incorporation of artificial intelligence and machine learning, a transition toward domestic healthcare, patient-oriented strategies, and the mushrooming of mobile health (mHealth) resolutions.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17209&type=smp
Which Market Dynamics Are Playing A Critical Role In The Growth Of The Non-Cystic Fibrosis Bronchiectasis Market?
The expanding occurrence of respiratory conditions is predicted to drive the non-cystic fibrosis bronchiectasis market’s growth in the future. Conditions impacting the lungs and respiratory system, influencing breathing and overall respiratory function, make up respiratory diseases. The escalating occurrence of such illnesses is predominantly due to growing environmental pollution, encompassing outdoor pollutants and indoor irritants like tobacco smoke. The expanded prevalence of respiratory infections provides prospects for enhancing the comprehension, diagnosis, and management of non-cystic fibrosis bronchiectasis via focused interventions and public health initiatives. For example, a UK governmental entity, the Office for Health Improvement and Disparities, reported in June 2023 that a total of 4,622 notifications of scarlet fever Group A Streptococcus bacteria were received from week 37 to week 46 of the 2022-2023 season in England, with 851 notifications received in week 46 alone. These notifications significantly surpass the average of 1,294 notifications (ranging between 258 to 2,008) for the same weeks (37 to 46) during the preceding five years. Therefore, the escalating occurrence of respiratory illnesses is anticipated to stimulate the growth of the non-cystic fibrosis bronchiectasis market.
Which Sub-Segments Are Driving Growth Within The Non-Cystic Fibrosis Bronchiectasis Market?
The non-cystic fibrosis bronchiectasismarket covered in this report is segmented –
1) By Diagnosis: Computed Tomography (CT) Scan; Bronchoscopy; Chest X Ray; Lung Function; Sputum Culture Test; Blood Tests; Other Diagnosis Types
2) By Treatment: Surgery; Physiotherapy; Vaccination; Airway Pharmacotherapy; Antibiotics; Other Treatments
3) By End Use: Hospitals And Clinics; Ambulatory Care Centers; Other End Uses
Subsegments:
1) By Computed Tomography (CT) Scan: High-Resolution CT (HRCT); Standard CT
2) By Bronchoscopy: Flexible Bronchoscopy; Rigid Bronchoscopy
3) By Chest X-Ray: Standard Chest X-Ray; Digital Chest X-Ray
4) By Lung Function: Spirometry; Peak Flow Measurement
5) By Sputum Culture Test: Bacterial Culture; Fungal Culture; Viral Culture
6) By Blood Tests: Complete Blood Count (CBC); C-Reactive Protein (CRP); Immunoglobulin Levels
7) By Other Diagnosis Types: Sweat Test; Genetic Testing; Exhaled Nitric Oxide Test
What Future-Focused Trends Are Anticipated In The Non-Cystic Fibrosis Bronchiectasis Market?
Leading corporations within the non-cystic fibrosis bronchiectasis sector are concentrating on individualized medical tactics, such as nebulization formulations, to enhance drug delivery efficacy and patient adherence. These nebulization solutions employ state-of-the-art technology to accurately and effectively distribute respiratory medications, consequently improving patient adherence and treatment results. For example, in April 2022, the Italy-based global pharmaceutical corporation, Zambon S.P.A, obtained a designation from the US FDA for CMS I-neb therapy for individuals living with non-cystic fibrosis bronchiectasis (NCFB). CMS I-neb is an under-investigation treatment, anticipated to be the first of its kind inhaled therapy for adult patients with NCFB who are colonized with P. aeruginosa. NCFB is characterized as a chronic, ongoing, irreparable respiratory ailment. This breakthrough designation attests to the regulatory route for CMS I-neb in NCFB, potentially accelerating its development and review.
Which Players Are Shaping The Competitive Landscape Of The Non-Cystic Fibrosis Bronchiectasis Market?
Major companies operating in the non-cystic fibrosis bronchiectasis market are Pfizer Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc (GSK), Boehringer Ingelheim International GmbH, Viatris Inc, Teva Pharmaceutical Industries Ltd, Vertex Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr Reddy’s Laboratories Ltd, Chiesi Farmaceutici SpA, Lupin Limited, Zambon Company SpA, Sunovion Pharmaceuticals Inc, Insmed Incorporated, Genentech, Zydus Cadila, Santhera Pharmaceuticals, TSRL Inc
Access The Complete Report Here:
How Do Regional Dynamics Influence The Non-Cystic Fibrosis Bronchiectasis Market Performance?
North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2024. The regions covered in the non-cystic fibrosis bronchiectasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=17209&type=smp
Browse Through More Reports Similar to the Global Non-Cystic Fibrosis Bronchiectasis Market 2025, By The Business Research Company
Cystic Fibrosis Cf Therapeutics Global Market Report 2025
Idiopathic Pulmonary Fibrosis Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report
Polycystic Ovarian Syndrome Treatment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
